BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that Shalini Sharp, the company’s Chief Financial Officer, will hold a virtual presentation at the BofA Securities Global Health Care Conference on Thursday, May 14, 2020 at 10:20 AM ET.

10x Genomics, Inc. reported financial results for the quarter ended March 31, 2020.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2020, along with a corporate update and outlook for 2020.

GenMark Diagnostics, Inc. announced the closing of its previously announced underwritten public offering of 8,341,968 shares of its common stock, including the full exercise of the underwriters’ option to purchase additional shares, at the public offering price of $9.65 per share.

Retrophin, Inc. reported its first quarter 2020 financial results and provided a corporate update.

Evolus, Inc. reported financial results for the first quarter ended March 31, 2020 and provided a business update, including the impact of the COVID-19 pandemic.

Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported financial results for the fiscal 2020 third quarter ended March 31, 2020 as summarized below:

HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced that it will report its financial results for the first quarter ended March 31, 2020 after the market close on Wednesday, May 13, 2020.

TG Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2020 and recent company developments.

Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance